Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of GIA632 in adults with non-segmental vitiligo
NL-OMON61230Phase 2Recruiting
- Sponsor
- Novartis
- Start
- Sep 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Vitiligo comparing GIA632 dose arm(s) with Placebo (2 arms). Primary endpoint: Percentage change from baseline in Facial Vitiligo Area Scoring Index. Started Sep 2026; status: recruiting.
02
Drugs
GIA632
03
Conditions
Vitiligo
Beyond the preview
Go deeper on NL-OMON61230.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61230.